huayizhang
Lv0
0 积分
2022-11-18 加入
-
Modernizing the United States’ Public Health Infrastructure: A Position Paper From the American College of Physicians
4个月前
已完结
-
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
4个月前
已完结
-
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
4个月前
已完结
-
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
5个月前
已完结
-
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
5个月前
已完结
-
Equality of Opportunity in Health and Healthcare
9个月前
已完结
-
Influencing factors of serum complement C3、C4 in children with myasthenia gravis
1年前
已完结
-
Preliminary Outcomes of Orelabrutinib Plus RCHOP in Treatment-Naïve Patients with Double-Expression Diffuse Large B Cell Lymphoma
1年前
已完结
-
[Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)]
1年前
已完结
-
Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study
1年前
已完结